Barbara Schilberg JD Overview
- Firm
- BioAdvance Capti...
- Primary Position
-
Advisor
- Primary Industry
-
Healthcare
- Active Board Seats
-
6
- Med. Deal Size
-
- Med. Valuation
-
Barbara Schilberg JD General Information
Biography
Ms. Barbara Schilberg serves as an Advisor at BioAdvance Captial. Mr. Schilberg serves as a Board Member at IO Biosciences. She served as Managing Director and Chief Executive Officer at BioAdvance. She serves as a Board Member at Keriton and Mebias Discovery. She has more than 30 years of experience working with academic technologies and start-up companies in the life sciences sector. Under her leadership as Chief Executive Officer, BioAdvance has committed $21.8 million to 31 seed-stage companies and 24 pre-seed projects focusing on areas including Alzheimer's disease, cancer, diabetes, obesity, and infectious diseases. She is a board member of Immunome, Jenrin Discovery, Marillion Pharmaceuticals, Melior Pharmaceuticals, Novira Pharmaceuticals, and QR Pharma. As a senior executive with four emerging life sciences companies, her prior experience provides significant insight into the key elements needed to build successful companies including public and private financings, intellectual property protection, corporate partnering arrangements, and the management of research programs. She joined Cephalon in 1994 as Senior Vice President and General Counsel and as a member of the executive committee. As part of her responsibilities, she led a multi-disciplinary team charged with completing Phase III clinical trials and preparing a new drug application for Provigil (modafinil), which the FDA approved in December 1999. She joined Incara Pharmaceuticals in 1998 as Executive Vice President and General Counsel, where she managed a research operation in Princeton, NJ engaged in discovering new antibacterial therapeutics. She continued in that capacity after the operation's acquisition by Advanced Medicine (now Theravance) in 2000. She also served as Vice President and General Counsel at Locus Discovery, Inc., an emerging pharmaceutical company in Blue Bell, PA engaged in computational drug design. She received a J.D. from the University of Virginia and clerked with the Honorable Edward R. Becker, now Senior Judge of the U.S. Court of Appeals for the Third Circuit. She served as a Board Member at Merganser Biotech.
Contact Information
Barbara Schilberg JD Board Seats (6)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
ENB Therapeutics | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | New York, NY | |
IO BiO Sciences | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Doylestown, PA | |
Jenrin Discovery | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Chadds Ford, PA | |
Keriton | Enterprise Systems (Healthcare) | Privately Held (backing) | Venture Capital-Backed | Philadelphia, PA | |
Mebias Discovery | Drug Discovery | Privately Held (backing) | Venture Capital-Backed | Philadelphia, PA |
Barbara Schilberg JD Lead Partner on Deals (42)
Barbara Schilberg JD has been the lead partner on 42 deals. Their latest deal was with Keriton, a enterprise systems (healthcare) company. The deal was made for on 14-Jun-2020.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
Keriton | 14-Jun-2020 | Early Stage VC (Series A) | Completed | Enterprise Systems (Healthcare) | Philadelphia, PA | |
Palvella Therapeutics | 28-May-2020 | Completed | Drug Discovery | Wayne, PA | ||
ENB Therapeutics | 27-Feb-2020 | Completed | Drug Discovery | New York, NY | ||
Palvella Therapeutics | 12-Aug-2019 | Completed | Drug Discovery | Wayne, PA | ||
Pillo Health | 29-May-2019 | Completed | Other Healthcare Technology Systems | Boston, MA | ||
IO BiO Sciences | 04-Jan-2019 | Completed | Drug Discovery | Doylestown, PA | ||
Pillo Health | 14-Jun-2018 | Completed | Other Healthcare Technology Systems | Boston, MA | ||
Jenrin Discovery | 25-Apr-2018 | Completed | Drug Discovery | Chadds Ford, PA | ||
IO BiO Sciences | 29-Mar-2018 | Seed Round | Completed | Drug Discovery | Doylestown, PA | |
Opsidio | 31-Jan-2018 | Later Stage VC | Completed | Drug Discovery | Bryn Mawr, PA |
Barbara Schilberg JD Network (200)
Board Members (63)
Name | Company | Representing | Location | From |
---|---|---|---|---|
Philip Wagenheim | Immunome (acquired in 2023) | Self | Bothell, WA | |
Michael Widlitz MD | Immunome (acquired in 2023) | Self | Bothell, WA | |
Immunome (acquired in 2023) | BioAdvance Captial | Bothell, WA | ||
ENB Therapeutics | Self | New York, NY | ||
Annovis Bio | Self | Malvern, PA |
Portfolio Executives (133)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Richard Mager | Keriton | Co-Chief Executive Officer & Board Member | 14-Jun-2020 | Philadelphia, PA |
Roy Rosin | Keriton | Advisor | 14-Jun-2020 | Philadelphia, PA |
Keriton | Co-Founder, Chief Executive Officer, Chief Technology Officer, Board Member and Manager | 14-Jun-2020 | Philadelphia, PA | |
Keriton | Chief Technology Officer | 14-Jun-2020 | Philadelphia, PA | |
Keriton | Chief Executive Officer & President | 14-Jun-2020 | Philadelphia, PA |
Fund Team Members (4)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Frederick Jones MD | BioAdvance Captial | Greenhouse Fund | Conshohocken, PA |
Gregory Harriman MD | BioAdvance Captial | Greenhouse Fund | Conshohocken, PA |
BioAdvance Captial | Conshohocken, PA | ||
BioAdvance Captial | Conshohocken, PA |
Barbara Schilberg JD Affiliated Funds (1)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Greenhouse Fund | BioAdvance Captial | Venture - General | Closed | 2003 |
Barbara Schilberg JD Advisory Roles (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
BioAdvance Captial | Investor | Advisor | Conshohocken, PA | Venture Capital |
Barbara Schilberg JD FAQs
-
Who is Barbara Schilberg JD?
Ms. Barbara Schilberg serves as an Advisor at BioAdvance Captial.
-
How much does Barbara Schilberg JD typically invest?
Barbara Schilberg JD's median deal size is
. -
What is Barbara Schilberg JD’s main position?
Barbara Schilberg JD’s primary position is Advisor.
-
How many active board seats does Barbara Schilberg JD hold?
Barbara Schilberg JD holds 6 board seats including ENB Therapeutics, IO BiO Sciences, Jenrin Discovery, Keriton, and Mebias Discovery.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »